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Abstract: Melatonin (Mel) is the major biologically active molecule secreted by the pineal gland. Mel
and its metabolites, 6-hydroxymelatonin (6(OH)Mel) and 5-methoxytryptamine (5-MT), possess a
variety of functions, including the scavenging of free radicals and the induction of protective
or reparative mechanisms in the cell. Their amphiphilic character allows them to cross cellular
membranes and reach subcellular organelles, including the mitochondria. Herein, the action of
Mel, 6(OH)Mel, and 5-MT in human MNT-1 melanoma cells against ultraviolet B (UVB) radiation
was investigated. The dose of 50 mJ/cm2 caused a significant reduction of cell viability up to
48%, while investigated compounds counteracted this deleterious effect. UVB exposure increased
catalase activity and led to a simultaneous Ca++ influx (16%), while tested compounds prevented
these disturbances. Additional analysis focused on mitochondrial respiration performed in isolated
mitochondria from the liver of BALB/cJ mice where Mel, 6(OH)Mel, and 5-MT significantly enhanced
the oxidative phosphorylation at the dose of 10−6 M with lower effects seen at 10−9 or 10−4 M.
In conclusion, Mel, 6(OH)Mel and 5-MT protect MNT-1 cells, which express melatonin receptors
(MT1 and MT2) against UVB-induced oxidative stress and mitochondrial dysfunction, including the
uncoupling of oxidative phosphorylation.
Keywords: metabolites of melatonin; melanoma cells; mitochondria; catalase; oxidative phosphorylation;
calcium homeostasis; ultraviolet radiation
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1. Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is a ubiquitous physiological mediator that is found
throughout the evolutionary scale of animals and is also in plants and unicellular organisms [1–5].
In mammals, it is characterized as a natural neurohormone synthesized in the pineal gland,
which is involved in the regulation of circadian rhythms [4]. In addition, many other tissues
and cells, including bone marrow [6], lymphocytes [7], retina [8], astrocytes [9], thymus [10],
skin [11–13], and female reproductive organs (granulosa cells, cumulus cells, and oocytes) [14],
can synthesize melatonin. There is also evidence that melatonin is present in follicular fluid [15],
and that it can be synthesized by oocytes [16,17]. Chemically, melatonin can function as an
endogenous free radical scavenger and a broad spectrum antioxidant, and it can easily reach
all cellular compartments because of its well-described amphiphilic nature [18–20]. Indeed,
melatonin is ubiquitously localized in the cytosolic, membranous, mitochondrial, and nuclear
compartments of the cell [21,22]. Interestingly, the highest melatonin concentrations are found
in mitochondria [23], raising the possibility of the functional significance for this targeting with
involvement in mitochondrial activities. For instance, most apoptotic signals originate in the
mitochondria, and melatonin has well-known anti-apoptotic [24–26], anti-inflammatory [27] and
prodifferentiation effects [28–30]. Mitochondria are also the organelles with the highest production
rate of reactive oxygen/nitrogen species (ROS/RNS), which are attenuated by melatonin [31] through
stimulation of the activity of anti-oxidative enzymes such as catalase (CAT), glutathione peroxidase
(GPx), superoxide dismutase (SOD) [32], heme oxygenase-1 (HO-1), γ-glutamylcysteine synthetase
(γ-GCS), and NADPH:quinone dehydrogenase-1 (NQO-1), which were induced via activation of
nuclear erythroid 2-related factor (Nrf2) [26,33]. UVB itself affects Nrf2 and suppresses Nrf2-dependent
gene expression in human skin [34]. It is recognized that mitochondria are the main target of the
environmental stress factors, one of them represented by ultraviolet radiation (UVR). Exposure of
the skin to UVB induces direct DNA damage [35] such as cyclobutane pyrimidine dimers (CPD)
and pyrimidine photoproducts (6-4-PPs) [36–39] with the additional production of reactive oxygen
species (ROS) induced by UVA [40,41]. Collectively, these changes have detrimental effects that include
carcinogenesis, cell senescence, and other skin pathologies [42]. Many melatonin actions are mediated
through its interaction with membrane bound type 1 and 2 (MT1 and MT2) receptors or through
receptor-independent mechanisms [30,43]. However, the metabolites of melatonin can also function as
antioxidants [26,33,44], and according to some authors as pro-oxidants [45].
Since melatonin interacts with lipid bilayers, herein on one hand, we investigated the action
of melatonin and its selected metabolites under UVR-induced stress conditions. On the other hand,
we tested the effect of compounds themselves on the bioenergetics of native isolated mitochondria
evaluating their respiratory capacity to understand a “real face” of melatonin’s capability to stabilize
mitochondrial homeostasis.
2. Results
2.1. Melatonin and Its Metabolites Mitigate UVB-Induced Cell Death
UVB induces serious intracellular disturbances such as DNA damage and the production of
ROS, leading to cell mortality or carcinogenesis. Firstly, we assessed the effect of UVB on the
viability of MNT-1 cells, and noticed a decrease in cell viability of approximately 52% (p < 0.001)
compared to the sham-irradiated controls, while melatonin as well as its metabolites themselves did
not affect the survival rate of MNT-1 cells, even at the highest tested concentration (10−3 M) (Figure 1,
insert). Subsequently, the dose-dependent (10−11–10−3 M) analysis was performed for melatonin
(Mel) (Figure 1A), 6-hydroxymelatonin (6(OH)Mel) (Figure 1CE) under ultraviolet B (UVB) exposure.
Pre-incubation with all three agents protected UVB-irradiated cells at the physiologic range of day and
night plasma levels, i.e. a concentration of 10−11 M by 8% (p < 0.05; Mel), 24% (p < 0.001; 6(OH)Mel),
and 19% (p < 0.001; 5-MT) or by 6% (p < 0.05; Mel), 13% (p < 0.01; 6(OH)Mel), and 13% (p < 0.05;
Int. J. Mol. Sci. 2018, 19, 3786 3 of 19
5-MT) for 10−9 M. Middle-range doses (10−8–10−6 M) still revealed the protective action of the tested
compounds; however, significant differences were moderate or none (10−6 M) in all of the cases.
Finally, the pharmacological doses (10−4 or 10−3 M) ameliorated a decrease in cell viability compared
to the UVR-treated cells by 13% (p < 0.01; Mel), 12% (p < 0.01; 6(OH)Mel), and 9% (p < 0.05; 5-MT) for
10−3 M. These data were also supported by crystal violet assessment, where UVB caused a dramatic
drop of MNT-1 proliferation ratio by 34% (p < 0.001) compared to the control cells, and pre-incubation
with Mel (Figure 1B), 6(OH)Mel (Figure 1D), or 5-MT (Figure 1F) significantly counteracted this effect.
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Figure 1. Ultraviolet radiation (UVR)-mediated reduction of viability is attenuated by melatonin, 6-
hydroxymelatonin (6(OH)Mel), and 5-methoxytryptamine (5-MT) in MNT-1 melanoma cells. 
Ultraviolet B (UVB)-irradiated (50 mJ/cm2) and non-irradiated cells (presented as inserts) were treated 
with graded concentrations of melatonin and its selected metabolites for 1 h prior to UVR. Viability 
was determined 48 h post-UVR by MTT assay (A,C,E) and crystal violet assessment (B,D,F), as 
described in the Section 4. Values were expressed as a percentage of the UVR-irradiated (50 mJ/cm2) 
or sham-irradiated sample (insert). Statistically significant differences versus control were indicated 
as * p < 0.05, ** p < 0.01, *** p < 0.001; with (# p < 0.001) indicating a significant difference between sham-
irradiated cell and UVR-exposed samples at particular concentrations. Red labeling indicates the 
effect of presence of tested compounds compared to UV-treated cells. 
2.2. Melatonin and Its Metabolites Protect MNT-1 Cells from UVB-Induced Oxidative Stress and 
Disturbances in Calcium Homeostasis 
Cells exposed to 50 mJ/cm2 UVB showed a twofold increase (p < 0.001) of catalase activity (CAT) 
activity compared to sham-irradiated samples (Figure 2; insert). Additionally, comparative analysis 
of melatonin actions revealed the strongest enhancing effect at a concentration of 10−3 M Mel by 28% 
(p < 0.001) compared to the control. At lower concentrations, this impact was less pronounced, e.g., 
11% (10−4 M), 13% (10−6 M) (p < 0.01), and 9% (10−9 M; not significant). The presence of metabolites of 
melatonin enhanced significantly CAT activity by 11% (10−9 M; p < 0.01) or by 9% (10−3 M; p < 0.01) for 
6(OH)Mel and 5-MT, respectively (Figure 2). UVB irradiation induced a massive calcium influx with 
16% (p < 0.001) more calcium inside the cell compared to the non-irradiated cells (Figure 3; insert). 
Pre-incubation for 1 h with melatonin or its metabolites counteracted these effects modestly by 8% 
(10−9 M Mel; p < 0.01); 6% (10−9 M 6(OH)Mel; p < 0.05), and 4% (10−9 M 5-MT; not significant). The 
highest concentration (10−3 M) of the compound showed a similar pattern of regulation arresting 
calcium influx by 6%, 5%, and by 8%, respectively, for melatonin (p < 0.05), 6(OH)Mel, and 5-MT (p < 
0.05) (Figure 3).  
Figure 1. Ultraviolet radiation (UVR)-mediated reduction of viability is attenuated by melatonin,
6-hydroxymelatonin (6(OH)Mel), and 5-methoxytryptamine (5-MT) in MNT-1 melanoma cells.
Ultraviolet B (UVB)-irradiated (50 mJ/cm2) and non-irradiated cells (presented as inserts) were
treated with graded concentrations of melatonin and its selected metabolites for 1 h prior to UVR.
Viability was determined 48 h post-UVR by MTT assay (A,C,E) and crystal violet assessment (B,D,F),
as described in the Section 4. Values were expressed as a percentage of the UVR-irradiated (50 mJ/cm2)
or sham-irradiated sample (insert). Statistically significant differences versus control were indicated
as * p < 0.05, ** p < 0.01, *** p < 0.001; with (# p < 0.001) indicating a significant difference between
sham-irradiated cell and UVR-exposed samples at particular concentrations. Red labeling indicates the
effect of presence of tested compounds compared to UV-treated cells.
2.2. Melatonin and Its Metabolites Protect MNT-1 Cells from UVB-Induced Oxidative Stress and Disturbances
in Calcium Homeostasis
Cells exposed to 50 mJ/cm2 UVB showed a twofold increase (p < 0.001) of catalase activity (CAT)
activity compared to sham-irradiated samples (Figure 2; insert). Additionally, comparative analysis
of melatonin actions revealed the strongest enhancing effect at a concentration of 10−3 M Mel by
28% (p < 0.001) compared to the control. At lower concentrations, this impact was less pronounced,
e.g., 11% (10−4 M), 13% (10−6 M) (p < 0.01), and 9% (10−9 M; not significant). The presence of
metabolites of melatonin enhanced significantly CAT activity by 11% (10−9 M; p < 0.01) or by 9%
(10−3 M; p < 0.01) for 6(OH)Mel and 5-MT, respectively (Figure 2). UVB irradiation induced a massive
calcium influx with 16% (p < 0.001) more calcium inside the cell compared to the non-irradiated
cells (Fig re 3; insert). Pre-incubation f r 1 h with m lat nin or i s metabolites count racted these
effects mod stly by 8% (10−9 M el; p < 0.01); 6% (10−9 M 6(OH)Mel; p < 0.05), a d 4% (10−9 M
5-MT; no significan ). The highest concentratio (10−3 M) of the com ound showed a similar pattern
of regulation arresting calcium influx by 6%, 5%, and by 8%, respectively, for m latonin (p < 0.05),
6(OH)Mel, and 5-MT (p < 0.05) (Figure 3).
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Figure 2. Melatonin, 6(OH)Mel, and 5-MT affect catalase activity (CAT) under UVR-induced stress
condition in MNT-1 cells. Ultraviolet B (UVB)-irradiated (50 mJ/cm2) cells were pre-treated with
graded concentrations of melatonin and its selected metabolites for 1 h prior to UVR. CAT activity was
determined 48 h post-UVR by the colorimetric assay as described in the Section 4. Values were expressed
as percentage of the UVR-irradiated (50 mJ/cm2) or sham-irradiated sample (insert). Statistically
significant differences were indicated as * p < 0.05, ** p < 0.01, *** p < 0.001.
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2.3. Melatonin and Its Metabolites Maintain Mitochondrial Function
Since melatonin penetrates very easily through cellular membranes reaching numerous
intracellular organelles, we assessed the influence of melatonin and its selected metabolites on
mitochondrial function (Figure 4; Table 1). These analysis identified Mel, 6(OH)Mel, and 5-MT
as the compounds enhancing markedly (p < 0.01) oxidative phosphorylation at the dose of 10−6 M
with subtle (not significant) differences at 10−9 or 10−4 M. Surprisingly, the highest dose of 10−3 M for
all tested substances decreased prominently the OXPHOS coupling efficiency (p < 0.001 or p < 0.01).
Evaluation of the mitochondrial metabolic states (Table 1) showed that in “native” conditions (without
stress), lower concentrations (10−9 or 10−6 M) of Mel, 6(OH)Mel, and 5-MT are more optimal than
the pharmacological ones for maintenance of the mitochondrial homeostasis. MNT-1 cells express
enzymes that play key roles in the synthesis of melatonin, including tryptophan-5-hydroxylase (TPH),
and hydroxyindole-O-methyl transferase (HIOMT), and show the presence of MT1 and MT2 (Figure 5).
This is consistent with previous reports on the capability of human melanoma cells to produce and
metabolize melatonin [46] and the expression of TPH1 in human melanoma skin biopsies [47] and
rodent melanomas [48,49].
Table 1. Effect of melatonin and its metabolites on the bioenergetics of mitochondria.
Non-phosphorylating LEAK respiration (state NL), OXPHOS capacity (state NP), integrity of the
outer mitochondrial membrane: (state NC), and NADH and succinate (NS)-linked OXPHOS capacity
(state NSP) were measured in liver mitochondria incubated without or in presence of melatonin (Mel),
6(OH)Mel, or 5-MT. Results are presented as the mean ± SEM. Statistically significant differences
compared to mitochondria without tested compounds (control) were presented as follows: * p < 0.05, **
p < 0.01, *** p < 0.001.
EtOH (control) 10−9 M 10−6 M 10−4 M 10−3 M
State NL
Melatonin
14.95 ± 0.50
12.87 ± 0.84 * 12.76±1.25 * 14.60±0.94 18.13±1.03
6-OH-melatonin 15.31 ± 0.70 14.40 ± 0.54 16.45 ± 0.65 18.97 ± 0.97
5-MT 12.80 ± 0.39 ** 11.97 ± 0.32 ** 16.91 ± 0.48 24.25 ± 0.88 **
State NP
Melatonin
79.04 ± 2.34
64.90 ± 2.34 * 74.19 ± 2.85 73.84 ± 3.50 64.56 ± 3.16 *
6-OH-melatonin 91.75 ± 1.02 * 88.82 ± 2.75 * 76.72 ± 2.55 50.27 ± 1.79 **
5-MT 62.16 ± 2.52 ** 74.67 ± 0.81 81.61 ± 2.14 75.62 ± 1.72
State NC (% of corresponding state NP)
Melatonin
121.10 ± 2.01
123.80 ± 1.15 116.30 ± 0.73 119.10 ± 1.83 112.80 ± 1.27
6-OH-melatonin 118.30 ± 0.74 125.20 ± 2.44 150.60 ± 1.61 *** 203.60 ± 15.11 **
5-MT 124.80 ± 1.68 115.20 ± 4.27 119.60 ± 0.93 116.00 ± 0.93
State NSP
Melatonin
300.00 ± 9.64
248.90 ± 8.65 * 262.00 ± 8.30 267.30 ± 12.61 266.10 ± 9.90
6-OH-melatonin 327.10 ± 3.51 * 328.00 ± 3.95 ** 368.90 ± 5.22 *** 311.60 ± 9.66
5-MT 260.00 ± 9.53 280.60 ± 3.97 313.30 ± 1.30 295.90 ± 3.41
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Figure 5. Evaluation of expres ion of enz ti g cutaneous melato in biosynthetic pathway
(tryptophan-5-hydroxylase (TPH1) an h i le-O-methyl transferase (HIOMT)) as well as
melatoni membrane receptors (MT1 an M 2) i arallel to housekeeping gene glyceraldehyde
phosphate dehydrogenase (GAPDH) in intact MNT-1 cells using specific primers (Table 2).
3. Discussion
Cutaneous cells are under the const n nflu nce of multiple environmental stres ors [50],
including UVR, which is the main source of generation of reactive oxygen/nitro en species (ROS/RNS),
leading to deleterious oxidative skin damage [40,42,51] that includes cell senescence, photoaging,
carcinogenesis, or inflammation. Thus, searching for the sun damage-preventing natural compounds
that can counteract UVB-induced increase in levels of ROS/RNS is strongly desired. One of such
compounds is melatonin, which possesses enhancing capacities regarding skin protection against
UVR [29,32,52]. It is commonly known as a free radical scavenger [53,54]; it detoxifies NO [55], H2O2,
O2 − [56,57], and OH [58]. To date, studies have shown the potential beneficial effects of melatonin
in the treatment of many chronic diseases, while it exhibits low or absent toxicity [59]. Additionally,
it exhibits Nrf2-mediated protective effects in animal models [23] or cutaneous cells [27,33]. Apart from
its significant anti-oxidative properties, melatonin also preserves mitochondrial function in different
in vitro and in vivo models [23,60–62]. Previous reports [63,64] claim that melatonin should be
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considered as a critical modulator of mitochondrial integrity and physiology in skin cells [26], and this
function can be also assigned to its metabolites [65]. This assumption has been substantiated in
several mitochondrial-related disorders such as murine models of Parkinson’s disease [66–68], and the
direct action of melatonin and metabolites on mitochondrial homeostasis [69,70]. This experimental
evidence identifies mitochondria as a likely site of melatonin synthesis [71], placing this compound as a
strategic molecule during the evolution of aerobic eukaryotes [72]. Our data confirmed that melatonin
and its selected metabolites can protect cells from UVB-mediated oxidative stress by enhancing the
activity of catalase, decreasing Ca++ influx, and maintaining mitochondrial function. It should be still
noted that melatonin, 6(OH)Mel, or 5-MT, particularly at pharmacological doses (10−3 M), seem to
affect mitochondrial function in the absence of any exogenous stressors (Figure 4). Interestingly,
these concentrations were found to be the most protective under UVB treatment. Thus, we assume
that in normal conditions at higher concentrations (10−3/10−4 M), the mitochondrial fission could
occur, but this hypothesis remains to be clarified. On the other hand, we propose that melatonin
may act as a sort of “standby molecule” or “cellular guardian” whose anti-oxidative capacities are
activated in case of cell stress. Indeed, it was reported in rat heart mitochondria that melatonin
inhibits stress-induced mitochondrial permeability transition pore (mPTP) opening and release of
cytochrome c [73,74]. It is also known that treatment with melatonin at a pharmacological dose
(10−3 M) affects mitochondrial function [75,76], which is consistent with our results performed on
isolated mitochondria. Moreover, Odinokova et al. [77] showed that melatonin drastically decreases
the expression of complex I subunit, which is accompanied by the suppression of ROS production
and the inhibition of mPTP opening. As we noticed here, the mechanism of action of melatonin is
complexed, and G protein-coupled melatonin type 1 and type 2 receptors (MT1 and MT2) as well as
key enzymes (TPH1 and HIOMT) for its synthesis are expressed in MNT-1 cells. According to the
earlier detections, melatonin receptors have been reported in melanocytes (normal and malignant),
keratinocytes (normal), or dermal fibroblasts [30,78–81]. The expression of both MT1 and MT2 receptors
in MNT-1 melanoma cells suggests that they might be involved in a regulation of calcium homeostasis
in this cell line under stress conditions. However, it is well described that calmodulin is another
melatonin-binding protein, which may be physiologically relevant to affinity after Ca++ binding
and interaction with calmodulin-controlled enzymes, including calmodulin kinase II (CaMKII) and
calcineurin (Cn), which regulate intracellular calcium homeostasis [11,82]. These observations may
partially explain the role of melatonin and its metabolites in the endoplasmic reticulum stress response,
as well as the regulation of apoptosis, autophagy, and mitochondrial function [83]. In addition,
Martin et al. [62] observed that melatonin arrested ruthenium red (RR)-mediated oxidative stress and
mitochondrial uncoupling where RR is a molecule that inhibits the mitochondrial Ca++ uniporter. Also,
our previous experiments [28,84] showed that melatonin in the skin is rapidly metabolized and/or
degraded through both indolic and kynuric pathways. The indolic pathway produces 6(OH)Mel as
the main product and 5-MT as a minor one, and these two metabolites of melatonin are produced
in skin cells [28]; similar effects are also observed in the kidney. Thus, the predominant pathway of
melatonin metabolism in all of the main skin cell populations (human normal epidermal keratinocytes
and melanocytes, human normal dermal fibroblasts) and malignant melanoma cells is similar to that
described at the systemic level, in which 6(OH)Mel is the main degradation product [65].
As mentioned above, mitochondria are one of the main target organelles for melatonin and play
the key role in disease initiation and/or progression. Although restoring mitochondrial function and
redox balance/signaling is not a straightforward process, mitochondria can convert external stimuli
into alterations in antioxidant defense mechanisms and energetic demands, making cells resistant to
stress. This phenomenon is known as mitohormesis, and is detrimental for restoring mitochondrial
function and control/regulation in non-physiological mtROS production. Since melatonin and
its metabolites over the years have been described as effective anti-inflammatory, anti-oxidative
and anti-apoptotic agents, also under UVR conditions (Figure 6), the development of novel
mitochondria-targeted multi-functional antioxidants based on melatonin are of great interest in skin
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biology and physiology [11,26]. These compounds maintaining mitochondrial homeostasis by direct
scavenging mtROS can increase cell resistance to stress and viability; therefore, it should be taken
under consideration as possible future drugs to improve mitochondrial health in primary and/or
secondary mitochondrial-related diseases.
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4. Materials and Methods
4.1. Reagents
Dulbecco’s modified Eagle’s medium (DMEM) with high glucose (4500 mg/L),
1% penicillin-streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in
1 mL 0.9% NaCl), EGTA, ethanol, HEPES (1 M), isopropanol, KH2PO4, mannitol, MgCl2·6H2O, MTT,
non-essential amino acids (NEAA) (100×), L-glutamic acid, L-malic acid, potassium lactobionate,
sodium pyruvate, sodium pyruvate solution (100 mM), succinic acid, and taurine were purchased
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from Sigma (St. Louis, MO, USA). Fetal bovine serum, 0.05% trypsin/0.53 mM EDTA solution, 1× PBS
(pH 7.4), L-glutamine (200 mM) were supplied by Thermo Fisher Scientific (Waltham, MA, USA).
4.2. Cell Culture
MNT-1 human melanotic cells were acquired as a gift from Dr. Cédric Delevoye (Institute Curie,
Paris, France). Cells were maintained in T-75 or T-175 flasks in DMEM medium supplemented
with 20% (v/v) heat-inactivated fetal bovine serum, 2 mM of L-glutamine, 10 mM of HEPES, 1 mM
of sodium pyruvate, 1% (v/v) NEAA, and 1% (v/v) streptomycin-penicillin solution at 37 ◦C in a
humidified atmosphere of 5% CO2 in air. Cells in the logarithmic growth phase were used in all of the
experiments, while 80–90% monolayers of confluent MNT-1 cells were harvested with a mixture of
0.05% trypsin–EDTA solution.
4.3. Pre-incubation with Melatonin, Its Metabolites, and UV Irradiation
Prior to the start of the experimental treatments, cells were cultured in normal medium for 24 h
in order to attach to the bottom of the culture dish. Thereafter, culture medium was replaced with
medium containing Mel, 6(OH)Mel, 5-MT, or solvent (control) (Sigma). Compounds were dissolved in
absolute ethanol and further diluted with phosphate-buffered saline (1× PBS, pH 7.4) to yield 10−2 M
stock solution, then diluted 1:10 with culture medium to yield a final wide concentration range of
powers of 10 from 10−3 to 10−11 M for cell culture pre-incubation. Melatonin-free, 6(OH)Mel-free,
or 5-MT-free medium served as controls. After 1 h pre-incubation with test compounds, cells were
washed twice with 1× PBS to remove remnants of medium, and fresh 1× PBS was added prior to
UVR exposure. Irradiation was performed using an irradiation bank consisting of six UV bulbs (TL12,
Philips, The Netherlands) that emit most of their energy within the UVB range (280–320 nm) with
an emission peak of 313 nm. UVB doses of 0 and 50 mJ/cm2 were used, and UVR-treated cells were
examined 48 h post-UVR. Sham-irradiated samples (0 mJ/cm2) were prepared using a culture dish
covered with aluminum foil and were considered as the control value. After UVR exposure, cells were
cultured and then subjected to the particular measurements.
4.4. MTT Viability Assay
Tested cells were seeded on 96-well plates at the density of 0.15 × 105 cells/well in the culture
medium, and thereafter grown to subconfluence (as judged from light microscopy). Following the
pre-incubation with tested compounds, cells were UV-irradiated in presence of 100 µL of pre-warmed
1× PBS, and then cultured until the desired time end-point. Cell viability was evaluated by MTT assay
based on the protocol described earlier by Carmichael et al. [85]. MTT (5 mg/mL) was dissolved in
1× PBS, sterilized by filtration through a 0.22-µM Millipore® filter and stored at 4 ◦C. After treatment
as described above, cells were washed twice with 1×PBS; then, 100 µL of MTT solution in culture
medium (the final dilution, 1:10) was added to each well. The cells were subsequently incubated
for 3 h at 37 ◦C to allow MTT metabolism. The formazan produced was dissolved in 100 µL of
isopropanol/0.04 N HCl, and absorbance was measured at 595 nm using a BioTek ELx808™ microplate
reader (BioTek Instruments, Inc., Winooski, VT, USA).
4.5. Crystal Violet Assessment
The proliferation of MNT-1 cells was assessed using ready-to-use crystal violet (CV) solution
(Cell Biolabs, Inc., San Diego, CA, USA). Cells were seeded on six-well plates (0.4–0.5 × 106 cells/cm2)
and experiments were performed when cultures reached 70–80% confluence. At the desired times,
cells were washed twice with 1× PBS, stained with 0.1% CV solution in 10% ethanol for 1 min,
and remnants were washed again with 1× PBS. Plates were photographed and the quantification of
cells was performed using ImageJ 1.51f software (National Institute of Health, Bethesda, MD, USA).
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4.6. Catalase Activity Assay
Evaluation of catalase (CAT) activity was conducted by colorimetric assays (BioVision Research
Products, Inc., Mountain View, CA, USA). Briefly, cells were seeded on six-well plates at the density and
cultured until reached confluency as described in point 4.5. At the desired times, cells were lysed with
catalase assay buffer and then centrifuged for 15 min at 10,000× g at 4 ◦C. Resultant supernatant was
proceeded for catalase reaction with one mM of H2O2 for 30 min at 25 ◦C, and arrested subsequently
with a stop solution. Catalase activity was determined by incubation at room temperature (RT) for
15 min with a develop mix containing catalase assay buffer, OxiRed™ Probe, and HRP solution.
The absorbance of tested samples was measured at 595 nm using a BioTek ELx808™ microplate reader
(BioTek Instruments, Inc., Winooski, VT, USA).
4.7. Calcium Assay
Intracellular calcium homeostasis was assessed by colorimetric assay supplied by BioVision
Research Products, Inc. After reaching desired confluency, cells were lysed and centrifuged for five min
at 16,000× g at 4 ◦C. The resultant supernatant was mixed with the chromogenic reagent, calcium assay
buffer, and then incubated at RT for 15 min protecting from light. The absorbance of tested samples
was measured at 595 nm using a BioTek ELx808™ microplate reader (BioTek Instruments, Inc.)
4.8. Animals and Isolation of Liver Mitochondria
All of the experimental procedures were performed in accordance with the principles of the
European animal research laws (European Communities Council Directive 2010/63/EU). Wild-type
female BALB/cJ mice (n = 8; weight: 20–25 g) were kept in an environmentally controlled room
(23 ± 1 ◦C with a 12-h light-dark cycle) receiving standard mice chow and water ad libitum. The mice
were euthanized by cervical dislocation. The liver mitochondria were isolated, as previously described
by Broekemeier et al. [86] with slight modification [87]. The liver was rapidly removed, weighed,
and placed in ice-cold mitochondrial buffer A (230 mM of mannitol, 70 mM of sucrose, three mM of
HEPES, 0.1 mM of EGTA; pH 7.4), and subsequently rinsed three times with buffer A. The liver was
minced with scissors and homogenized using a Teflon pestle homogenizer in buffer A (20 mL/1 g of
liver). The homogenate was centrifuged at 800× g for 10 min; then, the supernatant was decanted
and centrifuged at 4000× g for 10 min. The pellet was resuspended in 30 mL of suspension buffer B
(230 mM of mannitol, 70 mM of sucrose, 3 mM of HEPES), and centrifuged again at 7000× g for 10 min.
This step was repeated twice. The final mitochondrial pellet was resuspended in 0.5 mL of buffer B.
All of the steps were performed at 4 ◦C. Total protein concentration (20 to 30 mg of mitochondrial
protein per mL) was determined with the Bradford reagent (Bio-Rad Laboratories, Inc., Hercules, CA,
USA) [88].
4.9. High-Resolution Respirometry
Respiration was measured at 37 ◦C under constant stirring (750 rpm), which ensured a
homogenous oxygen distribution in the medium in a high-resolution respirometer using an
Oxygraph-2k (O2k, Oroboros Instruments, Innsbruck, Austria), a modular system for high-resolution
respirometry (HRR) according to Volani et al. [89]. Oxygen concentration (µM) and oxygen flux
per mass (pmol O2 s−1·mg−1) were recorded in real-time, while obtained data were evaluated
using DatLab software (Oroboros Instruments, Innsbruck, Austria). Briefly, mitochondrial respiration
was measured in MiR05 (mitochondrial respiration medium containing 0.5 mM of EGTA, 3 mM of
MgCl2·6H2O, 60 mM of potassium lactobionate, 20 mM of taurine, 10 mM of KH2PO4, 20 mM of
HEPES, 110 mM of sucrose, and 1 g/L of BSA fatty acid-free (pH 7.1) (MiR05; Oroboros Instruments,
Innsbruck, Austria). Freshly isolated liver mitochondria (0.1 mg of mitochondrial protein per each
2-mL chamber) used for respiration measurement were first incubated for 5 min in the medium without
(control) or in presence of Mel, 6(OH)Mel, or 5-MT.
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For the assessment of mitochondrial respiration, the following protocol was used:
(1) Non-phosphorylating LEAK respiration was assessed by injecting 10 mM of sodium pyruvate,
10 mM of L-glutamic acid (neutralized with KOH) and 2 mM of L-malic acid (neutralized with
KOH) as NADH (N)-linked substrates: state NL;
(2) OXPHOS capacity was induced by adding 1.25 mM of ADP at saturating concentration: state NP;
(3) 10 µM of cytochrome c was added to test the integrity of the outer mitochondrial membrane:
state NC;
(4) NADH and succinate (NS)-linked OXPHOS capacity was measured by adding 10 mM of succinic
acid (neutralized with KOH): state NSP.
4.10. Mitochondrial Quality and Control
The OXPHOS coupling efficiency was calculated as measures of mitochondrial quality and control.
OXPHOS coupling efficiency, calculated with the formula (1)—(state NL)/(state NP), reflects the
coupling of respiration supported by electron transferring flavoprotein (ETF) with pyruvate, glutamate,
and malate as substrates before (state NL) and after the addition of ADP (state NP). The OXPHOS
coupling efficiency (OCE) can be compared with the respiratory control ratio (RCR). The formula of
OCE could be rewritten as:
OCE =
(
1− 1
RCR
)
(1)
The OCE is noted between 0 and 1, while the RCR could be from 0 to infinite. A lower value of
OCE means lesser coupling of the oxidation and phosphorylation after the addition of ADP. As the
OCE decreases, it is therefore less coupled [90].
4.11. RNA Isolation, cDNA Synthesis, and PCR
RNA from MNT-1 cell pellet (5 × 106 cells) was extracted accordingly to the manufacturer’s
instructions using the innuPREP RNA Mini Kit (Analytik Jena, Berlin, Germany). The amount of
RNA was determined using BioPhotometer (Eppendorf, Hamburg, Germany). cDNA synthesis was
conducted using RevertAid™ First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham,
MA, USA) in the presence of oligo(dT) primers as follows: 65 ◦C for 5 min, 42 ◦C for 60 min, 70 ◦C for
5 min in Thermomixer (Eppendorf), and the resultant cDNA was stored at−20 ◦C prior to PCR reaction.
Reactions were carried out by GoTaq® PCR Master Mix (Promega GmbH, Mannheim, Germany) in
the presence of sequences of primers (Table 2). Amplification was performed using 10 min of initial
denaturation at 95 ◦C followed by three-step 39-cycling of 60 s at 95 ◦C (denaturation), 60 s at 60 ◦C
(annealing), and 60 s at 72 ◦C (extension). PCR products were separated on 1.8% agarose gel containing
RedSafe™ Nucleic Acid Staining solution (iNtRON Biotechnology, Sangdaewon-Dong, Korea),
and afterwards visualized using the Fusion-FX7 UV transilluminator (Vilber GmbH, Eberhardzell,
Germany). Samples were standardized by amplification of the housekeeping gene glyceraldehyde
phosphate dehydrogenase (GAPDH) [12]. DNA-standard O’GeneRuler™ 100 bp DNA Ladder Mix
from Fermentas International (Burlington, ON, Canada) was used.
4.12. Statistical Analysis
Data were expressed as pooled means (at least n = 3) ±standard error of the mean (SEM). The
data were analyzed using t-Test (for two groups) or with one-way ANOVA (for multiple groups) with
GraphPad Prism 7.05 software (La Jolla, CA, USA). Obtained data for MTT viability assay, crystal
violet assessment, CAT activity, or Ca++ homeostasis were normalized and expressed as a percentage
of the control value i.e., sham-irradiated sample (0 mJ/cm2, inserts) or UVB-exposed samples. The
results of mitochondrial metabolism were presented in arbitrary units. A p-value of less than 0.05 was
considered statistically significant.
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Table 2. The primers used for PCR, oriented 5’→3’.
Gene Primer Sequences Product Size (bp)
HIOMT F: TTCCAGGAAGGGGATTTCTR: GAAGCCAGCAGAAGAGAGGA 295
MT1 F: GCGTCCTCATCTTCACCATCR: GACGAGGAAGTGGAAAACCA 500
MT2 F: TATCACTGCCATCGCCATTAR: GAGGAGGAAGTGGATGACCA 244
TPH F: GACAACGTCCCCCATACTCTR: CATAGCCAAGTCCGCAAAAT 559
GAPDH F: AAGGTCATCCCTGAGCTGAAR: CCCCTCTTCAAGGGGTCTAC 498
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Abbreviations
5-MT 5-Methoxytryptamine
6(OH)Mel 6-Hydroxymelatonin
CAT Catalase
DMEM Dulbecco’s modified Eagle’s medium
HIOMT Hydroxyindole-O-methyl transferase
HRR High-resolution respirometry
Mel Melatonin
mPTP Mitochondrial permeability transition pore
OCE OXPHOS coupling efficiency
RCR Respiratory control ratio
RNS Reactive nitrogen species
ROS Reactive oxygen species
TEM Transmission electron microscopy
TPH Tryptophan-5-hydroxylase
UVR Ultraviolet radiation
References
1. Hardeland, R.; Fuhrberg, B. Ubiquitous melatonin—Presence and effects in unicells, plants and animals.
Trends Comp. Biochem. Physiol. 1996, 2, 25–45.
2. Kolar, J.; Machackova, I. Melatonin in higher plants: Occurrence and possible functions. J. Pineal Res. 2005,
39, 333–341. [CrossRef] [PubMed]
3. Paredes, S.D.; Korkmaz, A.; Manchester, L.C.; Tan, D.X.; Reiter, R.J. Phytomelatonin: A review. J. Exp. Bot.
2009, 60, 57–69. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3786 15 of 19
4. Reiter, R.J. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr. Rev.
1991, 12, 151–180. [CrossRef] [PubMed]
5. Tan, D.X.; Hardeland, R.; Manchester, L.C.; Paredes, S.D.; Korkmaz, A.; Sainz, R.M.; Mayo, J.C.;
Fuentes-Broto, L.; Reiter, R.J. The changing biological roles of melatonin during evolution: From an antioxidant
to signals of darkness, sexual selection and fitness. Biol. Rev. Camb. Philos. Soc. 2010, 85, 607–623. [CrossRef]
[PubMed]
6. Tan, D.X.; Manchester, L.C.; Reiter, R.J.; Qi, W.B.; Zhang, M.; Weintraub, S.T.; Cabrera, J.; Sainz, R.M.;
Mayo, J.C. Identification of highly elevated levels of melatonin in bone marrow: Its origin and significance.
Biochim. Biophys. Acta 1999, 1472, 206–214. [CrossRef]
7. Carrillo-Vico, A.; Calvo, J.R.; Abreu, P.; Lardone, P.J.; García-Mauriño, S.; Reiter, R.J.; Guerrero, J.M. Evidence
of melatonin synthesis by human lymphocytes and its physiological significance: Possible role as intracrine,
autocrine, and/or paracrine substance. FASEB J. 2004, 18, 537–539. [CrossRef] [PubMed]
8. Iuvone, P.M.; Tosini, G.; Pozdeyev, N.; Haque, R.; Klein, D.C.; Chaurasia, S.S. Circadian clocks, clock
networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog. Retin. Eye Res. 2005, 24,
433–456. [CrossRef] [PubMed]
9. Liu, Y.J.; Zhuang, J.; Zhu, H.Y.; Shen, Y.X.; Tan, Z.L.; Zhou, J.N. Cultured rat cortical astrocytes synthesize
melatonin: Absence of a diurnal rhythm. J. Pineal Res. 2007, 43, 232–238. [CrossRef] [PubMed]
10. Naranjo, M.C.; Guerrero, J.M.; Rubio, A.; Lardone, P.J.; Carrillo-Vico, A.; Carrascosa-Salmoral, M.P.;
Jiménez-Jorge, S.; Arellano, M.V.; Leal-Noval, S.R.; Leal, M.; et al. Melatonin biosynthesis in the thymus of
humans and rats. Cell. Mol. Life Sci. 2007, 64, 781–790. [CrossRef] [PubMed]
11. Slominski, A.T.; Hardeland, R.; Zmijewski, M.A.; Slominski, R.M.; Reiter, R.J.; Paus, R. Melatonin:
A cutaneous perspective on its production, metabolism, and functions. J. Investig. Dermatol. 2018, 138,
490–499. [CrossRef] [PubMed]
12. Slominski, A.; Pisarchik, A.; Semak, I.; Sweatman, T.; Wortsman, J.; Szczesniewski, A.; Slugocki, G.;
McNulty, J.; Kauser, S.; Tobin, D.J.; et al. Serotoninergic and melatoninergic systems are fully expressed in
human skin. FASEB J. 2002, 16, 896–898. [CrossRef] [PubMed]
13. Slominski, A.; Tobin, D.J.; Zmijewski, M.A.; Wortsman, J.; Paus, R. Melatonin in the skin: Synthesis,
metabolism and functions. Trends Endocrinol. Metab. 2008, 19, 17–24. [CrossRef] [PubMed]
14. Reiter, R.J.; Tamura, H.; Tan, D.X.; Xu, X.Y. Melatonin and the circadian system: Contributions to successful
female reproduction. Fertil. Steril. 2014, 102, 321–328. [CrossRef] [PubMed]
15. Shi, J.M.; Tian, X.Z.; Zhou, G.B.; Wang, L.; Gao, C.; Zhu, S.E.; Zeng, S.M.; Tian, J.H.; Liu, G.S. Melatonin exists
in porcine follicular fluid and improves in vitro maturation and parthenogenetic development of porcine
oocytes. J. Pineal Res. 2009, 47, 318–323. [CrossRef] [PubMed]
16. El-Raey, M.; Geshi, M.; Somfai, T.; Kaneda, M.; Hirako, M.; Abdel-Ghaffar, A.E.; Sosa, G.A.; El-Roos, M.E.;
Nagai, T. Evidence of melatonin synthesis in the cumulus oocyte complexes and its role in enhancing oocyte
maturation in vitro in cattle. Mol. Reprod. Dev. 2011, 78, 250–262. [CrossRef] [PubMed]
17. Sakaguchi, K.; Itoh, M.T.; Takahashi, N.; Tarumi, W.; Ishizuka, B. The rat oocyte synthesises melatonin.
Reprod. Fertil. Dev. 2013, 25, 674–682. [CrossRef] [PubMed]
18. Allegra, M.; Reiter, R.J.; Tan, D.X.; Gentile, C.; Tesoriere, L.; Livrea, M.A. The chemistry of melatonin’s
interaction with reactive species. J. Pineal Res. 2003, 34, 1–10. [CrossRef] [PubMed]
19. Rodriguez, C.; Mayo, J.C.; Sainz, R.M.; Antolin, I.; Herrera, F.; Martín, V.; Reiter, R.J. Regulation of antioxidant
enzymes: A significant role for melatonin. J. Pineal Res. 2004, 36, 1–9. [CrossRef] [PubMed]
20. Tan, D.X.; Reiter, R.J.; Manchester, L.C.; Yan, M.T.; El-Sawi, M.; Sainz, R.M.; Mayo, J.C.; Kohen, R.; Allegra, M.;
Hardeland, R. Chemical and physical properties and potential mechanisms: Melatonin as a broad spectrum
antioxidant and free radical scavenger. Curr. Top. Med. Chem. 2002, 2, 181–197. [CrossRef] [PubMed]
21. Menendez-Pelaez, A.; Reiter, R.J. Distribution of melatonin in mammalian tissues: The relative importance
of nuclear versus cytosolic localization. J. Pineal Res. 1993, 15, 59–69. [CrossRef] [PubMed]
22. Costa, E.J.; Shida, C.S.; Biaggi, M.H.; Ito, A.S.; Lamy-Freund, M.T. How melatonin interacts with lipid
bilayers: A study by fluorescence and ESR spectroscopies. FEBS Lett. 1997, 416, 103–106. [CrossRef]
23. Martín, M.; Macías, M.; Escames, G.; León, J.; Acuña-Castroviejo, D. Melatonin but not vitamins C and
E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress.
FASEB J. 2000, 14, 1677–1679. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3786 16 of 19
24. Andrabi, S.A.; Sayeed, I.; Siemen, D.; Wolf, G.; Horn, T.F. Direct inhibition of the mitochondrial permeability
transition pore: A possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J. 2004, 18,
869–871. [CrossRef] [PubMed]
25. Janjetovic, Z.; Nahmias, Z.P.; Hanna, S.; Jarrett, S.G.; Kim, T.K.; Reiter, R.J.; Slominski, A.T. Melatonin and its
metabolites ameliorate ultraviolet B-induced damage in human epidermal keratinocytes. J. Pineal Res. 2014,
57, 90–102. [CrossRef] [PubMed]
26. Slominski, A.T.; Zmijewski, M.A.; Semak, I.; Kim, T.K.; Janjetovic, Z.; Slominski, R.M.; Zmijewski, J.W.
Melatonin, mitochondria, and the skin. Cell. Mol. Life Sci. 2017, 74, 3913–3925. [CrossRef] [PubMed]
27. Kleszczyn´ski, K.; Zillikens, D.; Fischer, T.W. Melatonin enhances mitochondrial ATP synthesis, reduces
reactive oxygen species formation, and mediates translocation of the nuclear erythroid 2-related factor 2
resulting in activation of phase-2 antioxidant enzymes (γ-GCS, HO-1, NQO1) in ultraviolet radiation-treated
normal human epidermal keratinocytes (NHEK). J. Pineal Res. 2016, 61, 187–197. [PubMed]
28. Kim, T.K.; Kleszczyn´ski, K.; Janjetovic, Z.; Sweatman, T.; Lin, Z.; Li, W.; Reiter, R.J.; Fischer, T.W.;
Slominski, A.T. Metabolism of melatonin and biological activity of intermediates of melatoninergic pathway
in human skin cells. FASEB J. 2013, 27, 2742–2755. [CrossRef] [PubMed]
29. Slominski, A.T.; Kleszczyn´ski, K.; Semak, I.; Janjetovic, Z.; Zmijewski, M.A.; Kim, T.K.; Slominski, R.M.;
Reiter, R.J.; Fischer, T.W. Local melatoninergic system as the protector of skin integrity. Int. J. Mol. Sci. 2014,
15, 17705–17732. [CrossRef] [PubMed]
30. Slominski, R.M.; Reiter, R.J.; Schlabritz-Loutsevitch, N.; Ostrom, R.S.; Slominski, A.T. Melatonin membrane
receptors in peripheral tissues: Distribution and functions. Mol. Cell. Endocrinol. 2012, 351, 152–166.
[CrossRef] [PubMed]
31. Reiter, R.J.; Tan, D.X.; Cabrera, J.; D’Arpa, D. Melatonin and tryptophan derivatives as free radical scavengers
and antioxidants. Adv. Exp. Med. Biol. 1999, 467, 379–387. [PubMed]
32. Fischer, T.W.; Kleszczyn´ski, K.; Hardkop, L.H.; Kruse, N.; Zillikens, D. Melatonin enhances antioxidative
enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against the
formation of DNA damage (8-hydroxy-2′-deoxyguanosine) in ex vivo human skin. J. Pineal Res. 2013, 54,
303–312. [CrossRef] [PubMed]
33. Janjetovic, Z.; Jarrett, S.G.; Lee, E.F.; Duprey, C.; Reiter, R.J.; Slominski, A.T. Melatonin and its metabolites
protect human melanocytes against UVB-induced damage: Involvement of NRF2-mediated pathways.
Sci. Rep. 2017, 7, 1274. [CrossRef] [PubMed]
34. Kokot, A.; Metze, D.; Mouchet, N.; Galibert, M.D.; Schiller, M.; Luger, T.A.; Böhm, M. α-Melanocyte-
stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression
in human skin. Endocrinology 2009, 150, 3197–3206. [CrossRef] [PubMed]
35. Wondrak, G.T.; Roberts, M.J.; Cervantes-Laurean, D.; Jacobson, M.K.; Jacobson, E.L. Proteins of the
extracellular matrix are sensitizers of photo-oxidative stress in human skin cells. J. Investig. Dermatol.
2003, 121, 578–586. [CrossRef] [PubMed]
36. Ahmed, N.U.; Ueda, M.; Nikaido, O.; Osawa, T.; Ichihashi, M. High levels of 8-hydroxy-2′-deoxyguanosine
appear in normal human epidermis after a single dose of ultraviolet radiation. Br. J. Dermatol. 1999, 140,
226–231. [CrossRef] [PubMed]
37. Gilchrest, B.A.; Bohr, V.A. Aging processes, DNA damage, and repair. FASEB J. 1997, 11, 322–330. [CrossRef]
[PubMed]
38. Mouret, S.; Baudouin, C.; Charveron, M.; Favier, A.; Cadet, J.; Douki, T. Cyclobutane pyrimidine dimers are
predominant DNA lesions in whole human skin exposed to UVA radiation. Proc. Natl. Acad. Sci. USA 2006,
103, 13765–13770. [CrossRef] [PubMed]
39. Pfeifer, G.P.; Besaratinia, A. UV wavelength-dependent DNA damage and human non-melanoma and
melanoma skin cancer. Photochem. Photobiol. Sci. 2012, 11, 90–97. [CrossRef] [PubMed]
40. Heck, D.E.; Vetrano, A.M.; Mariano, T.M.; Laskin, J.D. UVB light stimulates production of reactive oxygen
species: Unexpected role for catalase. J. Biol. Chem. 2003, 278, 22432–22436. [CrossRef] [PubMed]
41. Swalwell, H.; Latimer, J.; Haywood, R.M.; Birch-Machin, M.A. Investigating the role of melanin in UVA/UVB-
and hydrogen peroxide-induced cellular and mitochondrial ROS production and mitochondrial DNA
damage in human melanoma cells. Free Radic. Biol. Med. 2012, 52, 626–634. [CrossRef] [PubMed]
42. Slominski, A.T.; Zmijewski, M.A.; Plonka, P.M.; Szaflarski, J.P.; Paus, R. How UV light touches the brain and
endocrine system through skin, and why. Endocrinology 2018, 159, 1992–2007. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3786 17 of 19
43. Lee, S.; Jin, J.X.; Taweechaipaisankul, A.; Kim, G.A.; Lee, B.C. Stimulatory effects of melatonin on porcine
in vitro maturation are mediated by MT2 receptor. Int. J. Mol. Sci. 2018, 19, 1581. [CrossRef] [PubMed]
44. Skobowiat, C.; Broz˙yna, A.A.; Janjetovic, Z.; Jeayeng, S.; Oak, A.S.W.; Kim, T.K.; Panich, U.; Reiter, R.J.;
Slominski, A.T. Melatonin and its derivatives counteract the ultraviolet B radiation-induced damage in
human and porcine skin ex vivo. J. Pineal Res. 2018, 65, e12501. [CrossRef] [PubMed]
45. Gurer-Orhan, H.; Suzen, S. Melatonin, its metabolites and its synthetic analogs as multi-faceted compounds:
Antioxidant, prooxidant and inhibitor of bioactivation reactions. Curr. Med. Chem. 2015, 22, 490–499.
[CrossRef] [PubMed]
46. Slominski, A.; Semak, I.; Pisarchik, A.; Sweatman, T.; Szczesniewski, A.; Wortsman, J. Conversion of
L-tryptophan to serotonin and melatonin in human melanoma cells. FEBS Lett. 2002, 511, 102–106. [CrossRef]
47. Slominski, A.; Pisarchik, A.; Johansson, O.; Jing, C.; Semak, I.; Slugocki, G.; Wortsman, J. Tryptophan
hydroxylase expression in human skin cells. Biochim. Biophys. Acta. 2003, 1639, 80–86. [CrossRef]
48. Slominski, A.; Pisarchik, A.; Semak, I.; Sweatman, T.; Szczesniewski, A.; Wortsman, J. Serotoninergic system
in hamster skin. J. Investig. Dermatol. 2002, 119, 934–942. [CrossRef] [PubMed]
49. Slominski, A.; Pisarchik, A.; Semak, I.; Sweatman, T.; Wortsman, J. Characterization of the serotoninergic
system in the C57BL/6 mouse skin. Eur. J. Biochem. 2003, 270, 3335–3344. [CrossRef] [PubMed]
50. Slominski, A.T.; Zmijewski, M.A.; Skobowiat, C.; Zbytek, B.; Slominski, R.M.; Steketee, J.D. Sensing the
environment: Regulation of local and global homeostasis by the skin’s neuroendocrine system. Adv. Anat.
Embryol. Cell Biol. 2012, 212, 1–115.
51. Bickers, D.R.; Athar, M. Oxidative stress in the pathogenesis of skin disease. J. Investig. Dermatol. 2006, 126,
2565–2575. [CrossRef] [PubMed]
52. Slominski, A.; Wortsman, J.; Tobin, D.J. The cutaneous serotoninergic/melatoninergic system: Securing a
place under the sun. FASEB J. 2005, 19, 176–194. [CrossRef] [PubMed]
53. Galano, A.; Tan, D.X.; Reiter, R.J. On the free radical scavenging activities of melatonin’s metabolites, AFMK
and AMK. J. Pineal Res. 2013, 54, 245–257. [CrossRef] [PubMed]
54. Reiter, R.J.; Melchiorri, D.; Sewerynek, E.; Poeggeler, B.; Barlow-Walden, L.; Chuang, J.; Ortiz, G.G.;
Acuña-Castroviejo, D. A review of the evidence supporting melatonin’s role as an antioxidant. J. Pineal Res.
1995, 18, 1–11. [CrossRef] [PubMed]
55. Blanchard, B.; Pompon, D.; Ducrocq, C. Nitrosation of melatonin by nitric oxide and peroxynitrite.
J. Pineal Res. 2000, 29, 184–192. [CrossRef] [PubMed]
56. Tan, D.X.; Manchester, L.C.; Reiter, R.J.; Plummer, B.F.; Limson, J.; Weintraub, S.T.; Qi, W. Melatonin directly
scavenges hydrogen peroxide: A potentially new metabolic pathway of melatonin biotransformation.
Free Radic. Biol. Med. 2000, 29, 1177–1185. [CrossRef]
57. Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: A
never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res. 2007,
42, 28–42. [CrossRef] [PubMed]
58. Tan, D.X.; Chen, L.D.; Poeggeler, B.; Manchester, L.C.; Reiter, R.J. Melatonin: A potent, endogenous hydroxyl
radical scavenger. Endocr. J. 1993, 1, 57–60.
59. Rondanelli, M.; Faliva, M.A.; Perna, S.; Antoniello, N. Update on the role of melatonin in the prevention of
cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances:
Review and remarks. Aging Clin. Exp. Res. 2013, 25, 499–510. [CrossRef] [PubMed]
60. Jou, M.J.; Peng, T.I.; Yu, P.Z.; Jou, S.B.; Reiter, R.J.; Chen, J.Y.; Wu, H.Y.; Chen, C.C.; Hsu, L.F. Melatonin
protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and
apoptosis. J. Pineal Res. 2007, 43, 389–403. [CrossRef] [PubMed]
61. León, J.; Acuña-Castroviejo, D.; Escames, G.; Tan, D.X.; Reiter, R.J. Melatonin mitigates mitochondrial
malfunction. J. Pineal Res. 2005, 38, 1–9. [CrossRef] [PubMed]
62. Martín, M.; Macías, M.; Escames, G.; Reiter, R.J.; Agapito, M.T.; Ortiz, G.G.; Acuña-Castroviejo, D.
Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial
damage induced by ruthenium red in vivo. J. Pineal Res. 2000, 28, 242–248. [CrossRef] [PubMed]
63. Hardeland, R.; Coto-Montes, A.; Poeggeler, B. Circadian rhythms, oxidative stress, and antioxidative defense
mechanisms. Chronobiol. Int. 2003, 20, 921–962. [CrossRef] [PubMed]
64. León, J.; Acuña-Castroviejo, D.; Sainz, R.M.; Mayo, J.C.; Tan, D.X.; Reiter, R.J. Melatonin and mitochondrial
function. Life Sci. 2004, 75, 765–790. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3786 18 of 19
65. Slominski, A.T.; Semak, I.; Fischer, T.W.; Kim, T.K.; Kleszczyn´ski, K.4; Hardeland, R.; Reiter, R.J. Metabolism
of melatonin in the skin: Why is it important? Exp. Dermatol. 2017, 26, 563–568. [CrossRef] [PubMed]
66. Antolín, I.; Mayo, J.C.; Sainz, R.M.; del Brío, M.A.; Herrera, F.; Martín, V.; Rodríguez, C. Protective effect of
melatonin in a chronic experimental model of Parkinson’s disease. Brain Res. 2002, 943, 163–173. [CrossRef]
67. Mayo, J.C.; Sainz, R.M.; Tan, D.X.; Antolín, I.; Rodríguez, C.; Reiter, R.J. Melatonin and Parkinson’s disease.
Endocrine 2005, 27, 169–178. [CrossRef]
68. Tapias, V.; Escames, G.; López, L.C.; López, A.; Camacho, E.; Carrión, M.D.; Entrena, A.; Gallo, M.A.;
Espinosa, A.; Acuña-Castroviejo, D. Melatonin and its brain metabolite N1-acetyl-5-methoxykynuramine
prevent mitochondrial nitric oxide synthase induction in Parkinsonian mice. J. Neurosci. Res. 2009, 87,
3002–3010. [CrossRef] [PubMed]
69. Semak, I.; Naumova, M.; Korik, E.; Terekhovich, V.; Wortsman, J.; Slominski, A. A novel metabolic pathway
of melatonin: Oxidation by cytochrome c. Biochemistry 2005, 44, 9300–9307. [CrossRef] [PubMed]
70. Semak, I.; Korik, E.; Antonova, M.; Wortsman, J.; Slominski, A. Metabolism of melatonin by cytochrome
P450s in rat liver mitochondria and microsomes. J. Pineal Res. 2008, 45, 515–523. [CrossRef] [PubMed]
71. Ahluwalia, A.; Brzozowska, I.M.; Hoa, N.; Jones, M.K.; Tarnawski, A.S. Melatonin signaling in mitochondria
extends beyond neurons and neuroprotection: Implications for angiogenesis and cardio/gastroprotection.
Proc. Natl. Acad. Sci. USA 2018, 115, E1942–E1943. [CrossRef] [PubMed]
72. Tan, D.X.; Manchester, L.C.; Liu, X.; Rosales-Corral, S.A.; Acuña-Castroviejo, D.; Reiter, R.J. Mitochondria
and chloroplasts as the original sites of melatonin synthesis: A hypothesis related to melatonin’s primary
function and evolution in eukaryotes. J. Pineal. Res. 2013, 54, 127–138. [CrossRef] [PubMed]
73. Petrosillo, G.; Colantuono, G.; Moro, N.; Ruggiero, F.M.; Tiravanti, E.; di Venosa, N.; Fiore, T.; Paradies, G.
Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability
transition pore opening. Am. J. Physiol. Heart Circ. Physiol. 2009, 297, 1487–1493. [CrossRef] [PubMed]
74. Suofu, Y.; Li, W.; Jean-Alphonse, F.G.; Jia, J.; Khattar, N.K.; Li, J.; Baranov, S.V.; Leronni, D.; Mihalik, A.C.;
He, Y.; et al. Dual role of mitochondria in producing melatonin and driving GPCR signaling to block
cytochrome c release. Proc. Natl. Acad. Sci. USA 2017, 114, E7997–E8006. [CrossRef] [PubMed]
75. Cheshchevik, V.T.; Dremza, I.K.; Lapshina, E.A.; Zabrodskaya, S.V.; Kujawa, J.; Zavodnik, I.B. Corrections by
melatonin of liver mitochondrial disorders under diabetes and acute intoxication in rats. Cell Biochem. Funct.
2011, 29, 481–488. [CrossRef] [PubMed]
76. Petrosillo, G.; di Venosa, N.; Pistolese, M.; Casanova, G.; Tiravanti, E.; Colantuono, G.; Federici, A.;
Paradies, G.; Ruggiero, F.M. Protective effect of melatonin against mitochondrial dysfunction associated
with cardiac ischemia-reperfusion: Role of cardiolipin. FASEB J. 2006, 20, 269–276. [CrossRef] [PubMed]
77. Odinokova, I.; Baburina, Y.; Kruglov, A.; Fadeeva, I.; Zvyagina, A.; Sotnikova, L.; Akatov, V.; Krestinina, O.
Effect of melatonin on rat heart mitochondria in acute heart failure in aged rats. Int. J. Mol. Sci. 2018, 19,
1555. [CrossRef] [PubMed]
78. Slominski, A.; Pisarchik, A.; Zbytek, B.; Tobin, D.J.; Kauser, S.; Wortsman, J. Functional activity of
serotoninergic and melatoninergic systems expressed in the skin. J. Cell. Physiol. 2003, 196, 144–153.
[CrossRef] [PubMed]
79. Cabrera, J.; Negrín, G.; Estévez, F.; Loro, J.; Reiter, R.J.; Quintana, J. Melatonin decreases cell proliferation
and induces melanogenesis in human melanoma SK-MEL-1 cells. J. Pineal Res. 2010, 49, 45–54. [CrossRef]
[PubMed]
80. Slominski, A.; Chassalevris, N.; Mazurkiewicz, J.; Maurer, M.; Paus, R. Murine skin as a target for melatonin
bioregulation. Exp. Dermatol. 1994, 3, 45–50. [CrossRef] [PubMed]
81. Slominski, A.; Pisarchik, A.; Wortsman, J. Expression of genes coding melatonin and serotonin receptors in
rodent skin. Biochim. Biophys. Acta. 2004, 1680, 67–70. [CrossRef] [PubMed]
82. León, J.; Macías, M.; Escames, G.; Camacho, E.; Khaldy, H.; Martín, M.; Espinosa, A.; Gallo, M.A.;
Acuña-Castroviejo, D. Structure-related inhibition of calmodulin-dependent neuronal nitric-oxide synthase
activity by melatonin and synthetic kynurenines. Mol. Pharmacol. 2000, 58, 967–975. [CrossRef] [PubMed]
83. Fernández, A.; Ordóñez, R.; Reiter, R.J.; González-Gallego, J.; Mauriz, J.L. Melatonin and endoplasmic
reticulum stress: Relation to autophagy and apoptosis. J. Pineal Res. 2015, 59, 292–307. [CrossRef] [PubMed]
84. Slominski, A.; Baker, J.; Rosano, T.G.; Guisti, L.W.; Ermak, G.; Grande, M.; Gaudet, S.J. Metabolism of
serotonin to N-acetylserotonin, melatonin, and 5-methoxytryptamine in hamster skin culture. J. Biol. Chem.
1996, 271, 12281–12286. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3786 19 of 19
85. Carmichael, J.; DeGraff, W.G.; Gazdar, A.F.; Minna, J.D.; Mitchell, J.B. Evaluation of a tetrazolium-based
semiautomated colorimetric assay; assessment of chemosensitivity testing. Cancer Res. 1987, 47, 936–942.
[PubMed]
86. Broekemeier, K.M.; Schmid, P.C.; Schmid, H.H.; Pfeiffer, D.R. Effects of phospholipase A2 inhibitors on
ruthenium red-induced Ca2+ release from mitochondria. J. Biol. Chem. 1985, 260, 105–113. [PubMed]
87. Flis, D.J.; Olek, R.A.; Kaczor, J.J.; Rodziewicz, E.; Halon, M.; Antosiewicz, J.; Wozniak, M.; Gabbianelli, R.;
Ziolkowski, W. Exercise-induced changes in caveolin-1, depletion of mitochondrial cholesterol, and the
inhibition of mitochondrial swelling in rat skeletal muscle but not in the liver. Oxid. Med. Cell. Longev. 2016,
2016, 3620929. [CrossRef] [PubMed]
88. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein
utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248–254. [CrossRef]
89. Volani, C.; Doerrier, C.; Demetz, E.; Haschka, D.; Paglia, G.; Lavdas, A.A.; Gnaiger, E.; Weiss, G. Dietary
iron loading negatively affects liver mitochondrial function. Metallomics. 2017, 9, 1634–1644. [CrossRef]
[PubMed]
90. Van Schaardenburgh, M.; Wohlwend, M.; Rognmo, Ø.; Mattsson, E.J.R. Exercise in claudicants increase or
decrease walking ability and the response relates to mitochondrial function. J. Transl. Med. 2017, 15, 130.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
